The pharmaceutical industry is bringing new drugs to market at the slowest rate in the history of modern drug discovery. A major factor responsible for this state of affairs is the failure to develop viable drug candidates once disease targets have been identified.

Traditional techniques for finding drug candidates are highly prone to failure. Two-thirds of discovery projects in the industry end without finding a single drug candidate, thus leaving many medical needs unfulfilled. The remaining projects typically have just one candidate that progresses through further development. When this single candidate fails during clinical testing, there is no suitable alternate to take its place. The consequence is the current industry-wide scarcity of new drugs in the pipelines. The need for a new discovery platform that can design novel drug candidates consistently and cost-effectively is urgent and acute.

Verseon's platform overcomes the drug candidate bottleneck. It can design multiple novel candidates per project, typically four to six, that are ready to go through human trials. A drug development project that begins with multiple drug candidates is able to take more "shots on the goal" and is far more likely to succeed in clinical trials, and satisfy our unmet medical needs.